Truist Financial
ONCY

Truist Financial’s Oncolytics Biotech ONCY Stock Holding History

Truist Financial’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17K Buy
+20,000
New +$19.9K ﹤0.01% 2779

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Truist Financial's ONCY Position: Q1 2026 in Review

Truist Financial opened a new position in Oncolytics Biotech (ONCY) in Q1 2026: 20,000 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #2779 among its holdings.

59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Truist Financial held 20,000 shares of Oncolytics Biotech worth $17K as of Q1 2026.
  • Oncolytics Biotech was a new Truist Financial position in Q1 2026.
  • Oncolytics Biotech made up ﹤0.01% of Truist Financial's portfolio in Q1 2026, its #2779 holding.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.